Millennium Management’s KalVista Pharmaceuticals KALV Stock Holding History

Millennium Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.5M	Sell	1,912,146 -984,520	-34%	-$15.9M	0.02%	1032
2025 Q4	$46.8M	Buy	2,896,666 +800,443	+38%	+$10.6M	0.02%	869
2025 Q3	$25.5M	Buy	2,096,223 +1,755,594	+515%	+$24.3M	0.01%	1403
2025 Q2	$3.85M	Buy	340,629 +142,424	+72%	+$1.74M	﹤0.01%	3251
2025 Q1	$2.29M	Buy	+198,205	New	+$2.02M	﹤0.01%	3662
2024 Q2	–	Sell	-19,329	Closed	-$229K	–	6236
2024 Q1	$229K	Buy	+19,329	New	+$258K	﹤0.01%	5303
2023 Q3	–	Sell	-27,935	Closed	-$251K	–	6346
2023 Q2	$251K	Sell	27,935 -52,768	-65%	-$487K	﹤0.01%	5001
2023 Q1	$634K	Sell	80,703 -395,548	-83%	-$2.95M	﹤0.01%	4451
2022 Q4	$3.22M	Sell	476,251 -1,707	-0.4%	-$9.14K	﹤0.01%	3167
2022 Q3	$6.93M	Buy	477,958 +377,641	+376%	+$5.28M	﹤0.01%	2566
2022 Q2	$987K	Buy	100,317 +83,169	+485%	+$917K	﹤0.01%	4377
2022 Q1	$253K	Buy	+17,148	New	+$246K	﹤0.01%	5693
2021 Q4	–	Sell	-36,715	Closed	-$641K	–	7117
2021 Q3	$641K	Buy	+36,715	New	+$744K	﹤0.01%	5114
2021 Q1	–	Sell	-28,797	Closed	-$547K	–	6239
2020 Q4	$547K	Sell	28,797 -33,981	-54%	-$583K	﹤0.01%	4121
2020 Q3	$790	Buy	62,778 +15,316	+32%	+$192K	﹤0.01%	3299
2020 Q2	$574K	Buy	+47,462	New	+$505K	﹤0.01%	3321
2020 Q1	–	Sell	-28,148	Closed	-$501K	–	4190
2019 Q4	$501K	Buy	28,148 +13,929	+98%	+$182K	﹤0.01%	3377
2019 Q3	$164K	Buy	14,219 +4,324	+44%	+$69.9K	﹤0.01%	3845
2019 Q2	$219K	Sell	9,895 -86,575	-90%	-$2.03M	﹤0.01%	3713
2019 Q1	$2.76M	Buy	+96,470	New	+$2.09M	﹤0.01%	2197
2018 Q4	–	Sell	-52,041	Closed	-$1.15M	–	3958
2018 Q3	$1.15M	Buy	52,041 +38,924	+297%	+$526K	﹤0.01%	2795
2018 Q2	$107K	Sell	13,117 -216,131	-94%	-$1.91M	﹤0.01%	3642
2018 Q1	$2.17M	Sell	229,248 -7,336	-3%	-$76.8K	﹤0.01%	2260
2017 Q4	$2.31M	Buy	+236,584	New	+$2.46M	﹤0.01%	2197
2016 Q3	–	Sell	-1,006	Closed	-$9K	–	3437
2016 Q2	$9K	Buy	+1,006	New	+$11.7K	﹤0.01%	3116

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management's KALV Position: Q1 2026 in Review

Millennium Management reduced its KalVista Pharmaceuticals (KALV) stake by 34% in Q1 2026, selling an estimated $15.9M and leaving 1,912,146 shares worth $38.5M. The position accounts for 0.02% of the portfolio, ranked #1032.

Millennium Management first reported a position in KALV in Q2 2016 and has held it in 25 quarters since. The position peaked at $46.8M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Millennium Management held 1,912,146 shares of KalVista Pharmaceuticals worth $38.5M as of Q1 2026.
Millennium Management sold 984,520 KalVista Pharmaceuticals shares in Q1 2026, an estimated $15.9M.
KalVista Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1032 holding.
Millennium Management first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 25 quarters since.
Millennium Management's KalVista Pharmaceuticals position peaked at $46.8M in Q4 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.